Nasdaq Stockholm Welcomes Scandinavian ChemoTech t

Stockholm, December 6, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Scandinavian ChemoTech AB’s shares (short name: CMOTEC B) commenced today on Nasdaq First North in Stockholm. Scandinavian ChemoTech (“ChemoTech”) belongs to the health care sector and is the 80 ^th company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.

ChemoTech is a Scandinavian healthcare company specialized in development of cancer and pain treatments. Its lead product, IQWave, is described as a next generation electrochemotherapy device that can be used for the treatment of a wide range of tumours. The company’s long term goal is to expand its portfolio into effective pain management for cancer patients and a minimally invasive treatment method for prostate cancer. ChemoTech was founded in 2015 and has its headquarters at the IDEON Science Park in Lund, Sweden. For more information, please visit www.chemotech.se .

”The Nasdaq listing of ChemoTech marks yet another milestone for our company,” said Mohan Frick, CEO of ChemoTech. “Addressing the vast, unmet need for efficient and cost effective cancer therapy has always been the main objective for ChemoTech and we strive to make a difference for cancer patients in many parts of the world. I am strengthened and encouraged by the support we have received from both current and new investors and look forward to the journey that lies ahead of us.”

“We welcome ChemoTech to Nasdaq First North, where it will make a compelling addition to our growing health care sector,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We congratulate ChemoTech on its listing and look forward to supporting the company for many years to come.”

Scandinavian ChemoTech AB has appointed Västra Hamnen Corporate Finance AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com .

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius .

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.